Patients that have received prior radiation therapy are eligible.Patient must not have received any prior treatment with an EGFR TKI or with an anti-VEGF agent.
Plasma, cytology, or tumor tissue can be utilized for mutation testing Test results originating from a Clinical Laboratory Improvement Act (CLIA)-certified or similarly accredited laboratory are acceptable no specific assay is mandated. Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions) are not eligible. but not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q, S768I). All staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 8th edition staging criteria
